Risk Factors for Morbidity and Mortality Following Hospitalization for Pericarditis.


Journal

Journal of the American College of Cardiology
ISSN: 1558-3597
Titre abrégé: J Am Coll Cardiol
Pays: United States
ID NLM: 8301365

Informations de publication

Date de publication:
01 12 2020
Historique:
received: 27 08 2020
revised: 25 09 2020
accepted: 25 09 2020
entrez: 27 11 2020
pubmed: 28 11 2020
medline: 4 3 2021
Statut: ppublish

Résumé

Viral or idiopathic pericarditis is a frequent condition, often considered benign, although prior studies have suggested that pericarditis is associated with both cardiovascular and noncardiovascular disease, for example, malignancy. This study sought to assess mortality risk and morbidity patterns in patients with incident viral or idiopathic pericarditis. In nationwide Danish registries, we identified patients discharged with a first-time diagnosis of pericarditis from 1996 to 2016. Patients with a severe underlying heart condition were excluded. The patients were matched 1:10 with individuals from the general population by sex and year of birth. We assessed 5-year mortality using Kaplan-Meier and Cox proportional hazards models adjusted for baseline comorbidities and identified subsequent hospital admissions. We identified 7,988 patients with pericarditis and 79,880 matched control individuals. The absolute 5-year survival probability was 92.9% and 95.8% in the pericarditis and control groups, respectively (adjusted hazard ratio: 1.31; 95% confidence interval: 1.13 to 1.52). The greatest difference in mortality was seen the first year, and it was primarily driven by the female part of the population. The incidence rate per 1,000 person-years of new-onset, admission-required diagnosis was higher in the pericarditis group both for cardiovascular and noncardiovascular diseases. We observed a higher mortality risk over 5 years in the pericarditis group, especially among the female patients, compared to matched control individuals. Furthermore, we observed a higher frequency of both cardiovascular and noncardiovascular hospital admissions, highlighting the need for focus on underlying morbidity in patients presenting with apparent viral or idiopathic pericarditis.

Sections du résumé

BACKGROUND
Viral or idiopathic pericarditis is a frequent condition, often considered benign, although prior studies have suggested that pericarditis is associated with both cardiovascular and noncardiovascular disease, for example, malignancy.
OBJECTIVES
This study sought to assess mortality risk and morbidity patterns in patients with incident viral or idiopathic pericarditis.
METHODS
In nationwide Danish registries, we identified patients discharged with a first-time diagnosis of pericarditis from 1996 to 2016. Patients with a severe underlying heart condition were excluded. The patients were matched 1:10 with individuals from the general population by sex and year of birth. We assessed 5-year mortality using Kaplan-Meier and Cox proportional hazards models adjusted for baseline comorbidities and identified subsequent hospital admissions.
RESULTS
We identified 7,988 patients with pericarditis and 79,880 matched control individuals. The absolute 5-year survival probability was 92.9% and 95.8% in the pericarditis and control groups, respectively (adjusted hazard ratio: 1.31; 95% confidence interval: 1.13 to 1.52). The greatest difference in mortality was seen the first year, and it was primarily driven by the female part of the population. The incidence rate per 1,000 person-years of new-onset, admission-required diagnosis was higher in the pericarditis group both for cardiovascular and noncardiovascular diseases.
CONCLUSIONS
We observed a higher mortality risk over 5 years in the pericarditis group, especially among the female patients, compared to matched control individuals. Furthermore, we observed a higher frequency of both cardiovascular and noncardiovascular hospital admissions, highlighting the need for focus on underlying morbidity in patients presenting with apparent viral or idiopathic pericarditis.

Identifiants

pubmed: 33243382
pii: S0735-1097(20)37419-2
doi: 10.1016/j.jacc.2020.09.607
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2623-2631

Commentaires et corrections

Type : CommentIn
Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2020 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Author Disclosures The authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Auteurs

Flora L Sigvardt (FL)

Copenhagen University Hospital, Herlev and Gentofte, Denmark. Electronic address: flora.sigvardt@gmail.com.

Morten L Hansen (ML)

Copenhagen University Hospital, Herlev and Gentofte, Denmark.

Søren L Kristensen (SL)

Department of Cardiology Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.

Finn Gustafsson (F)

Department of Cardiology Rigshospitalet, University of Copenhagen, Copenhagen, Denmark; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.

Muzhda Ghanizada (M)

Copenhagen University Hospital, Herlev and Gentofte, Denmark; Department of Cardiology Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.

Morten Schou (M)

Copenhagen University Hospital, Herlev and Gentofte, Denmark; Department of Cardiology Rigshospitalet, University of Copenhagen, Copenhagen, Denmark; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.

Lars Køber (L)

Department of Cardiology Rigshospitalet, University of Copenhagen, Copenhagen, Denmark; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.

Christian Torp-Pedersen (C)

Department of Cardiology and Clinical Research, Nordsjaellands Hospital, Hilleroed, Denmark.

Gunnar H Gislason (GH)

Copenhagen University Hospital, Herlev and Gentofte, Denmark; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark; The Danish Heart Foundation, Copenhagen, Denmark.

Christian Madelaire (C)

Copenhagen University Hospital, Herlev and Gentofte, Denmark.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH